Naltrexone/Bupropion

DRUG7 trials

Sponsors

Orexigen Therapeutics, Inc, Mayo Clinic, Gangnam Severance Hospital, Oslo University Hospital, Novo Nordisk A/S

Conditions

Breast CancerHealthy SubjectsObesityObesity, MorbidObesity; DrugOverweight

Phase 1

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

CompletedNCT02745912

Orexigen Therapeutics, IncHealthy Subjects

Start: 2016-04-30End: 2016-08-31Updated: 2016-09-29

Phase 3

Individualized Obesity Pharmacotherapy

CompletedNCT03374956

Mayo ClinicObesity

Start: 2017-12-11End: 2022-05-26Updated: 2023-07-18

Phase 4

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

WithdrawnNCT04399395

Oslo University HospitalObesity

Start: 2020-11-01End: 2022-12-31Updated: 2021-03-01

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

CompletedNCT05579249

Novo Nordisk A/SObesity

Start: 2023-01-19End: 2024-11-27Updated: 2026-01-14

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

RecruitingNCT06620562

Laval UniversityObesity; Drug, Obesity, Morbid

Start: 2025-06-04End: 2028-08-31Target: 108Updated: 2025-08-08

Unknown Phase

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

CompletedNCT03581630

Gangnam Severance HospitalBreast Cancer, Obesity, Overweight

Start: 2017-07-29End: 2018-07-22Updated: 2018-08-29

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruitingNCT05756764

Louisiana State University Health Sciences Center in New OrleansObesity

Start: 2023-06-01End: 2026-02-20Target: 30Updated: 2025-09-09

Related Papers

<p>Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial</p>

Diabetes Metabolic Syndrome and Obesity2020-09-0111 citations